NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Melanoma Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Melanoma

ECOG-ACRIN EA6134 - "A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma"

CANCER TYPE: Melanoma
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02224781
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Melanoma, unresectable, stage III or IV, BRAFV600 mutation, Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at progression VS. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at progression.






ECOG-ACRIN EA6141 - "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma"

CANCER TYPE: Melanoma
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02339571
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Melanoma, unresectable stage III or stage IV, Nivolumab + Ipilimumab + or - Sargramostim (GM-CSF)






SWOG S1320 - "A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma."

CANCER TYPE: Melanoma
RESEARCH BASE: SWOG
NCT NUMBER: 02196181
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Melanoma, Stg IV; intermittent vs continuous dosing of dabrafenib and trametinib






SWOG S1404 - A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma."

CANCER TYPE: Melanoma
RESEARCH BASE: SWOG
NCT NUMBER: NCT02506153
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Melanoma, resected, stage III & IV, Interferon or Ipilimumab vs MK-3475 (Pembrolizumab), evaluate PD-L1 expression









  © 2013-2017 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA